Overall rank by patents
#11,149
of 50,000 tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Adaptimmune Limited
USPTO PatentsView assignee record - 27 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).
27
Total patents granted
9
CPC technology areas
13.3
Avg claims per patent
+70%
5-year grant velocity
The verdict
According to USPTO PatentsView, Adaptimmune ranks #11,149 of 50,000 tracked US assignees by granted-patent volume, with 27 patents across 9 technology areas.
- #11,149
- of 50,000 US assignees by volume
- Top 41%
- by Innovation Score (38.4/100)
- 13.3
- avg claims per patent
- +70%
- grant velocity, last 5 yrs
Portfolio overview
Adaptimmune Limited has been granted 27 US utility patents between 2015 and 2024, placing Adaptimmune Limited at #11,149 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.3 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Adaptimmune Limited is one of the more focused assignees in the PatentsView dataset. By volume, Adaptimmune sits between Apollo Education Group, Inc. (27 patents, rank #11,154) and Akili Interactive Labs, Inc. (27 patents, rank #11,162) - the closest US assignees by grant volume. The composite Innovation Score of 38.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 17 grants, compared with 10 in the 2015–2019 window, a +70% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Adaptimmune Limited's 13.3 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 9 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Who files at Adaptimmune's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Apollo Education…
APOLLO EDUCATION GROUP, INC.
27 patents
- Arcadia Bioscienc…
ARCADIA BIOSCIENCES, INC.
27 patents
- Asahi Group Holdi…
ASAHI GROUP HOLDINGS, LTD.
27 patents
- ASSA Abloy Reside…
ASSA ABLOY RESIDENTIAL GROUP, INC.
27 patents
- Addepar
Addepar, Inc.
27 patents
- Advanced Flexible…
Advanced Flexible Circuits Co., Ltd.
27 patents
- Affirm
Affirm, Inc.
27 patents
- Akili Interactive…
Akili Interactive Labs, Inc.
27 patents
- Adaptimmune ◀
Adaptimmune Limited
27 patents
What this shows Adaptimmune holds 27 patents at rank #11,158, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Adaptimmune
By rank, the assignees closest to #11,158 in granted patent volume.
- Apollo Education Group, Inc. #11,154 · 27 patents
- Arcadia Biosciences, Inc. #11,155 · 27 patents
- Asahi Group Holdings, Ltd. #11,156 · 27 patents
- ASSA Abloy Residential Group, Inc. #11,157 · 27 patents
- Addepar, Inc. #11,159 · 27 patents
- Advanced Flexible Circuits Co., Ltd. #11,160 · 27 patents
- Affirm, Inc. #11,161 · 27 patents
- Akili Interactive Labs, Inc. #11,162 · 27 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Adaptimmune's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Adaptimmune's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
38 Top 41% higher than 59% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 7.4% |
| 2016 | 4 | 14.8% |
| 2017 | 1 | 3.7% |
| 2018 | 2 | 7.4% |
| 2019 | 1 | 3.7% |
| 2020 | 1 | 3.7% |
| 2021 | 6 | 22.2% |
| 2022 | 1 | 3.7% |
| 2023 | 4 | 14.8% |
| 2024 | 5 | 18.5% |
Which technologies does Adaptimmune Limited patent most?
Top 9 of 9 technology areas
Grant record at a glance
Portfolio Volume 27 grants
CPC subclasses 9
Avg. claims / grant 13.3
Velocity +70%
Historical grant data only; it does not rate legal strength or current strategy.
Frequently Asked Questions
Where does Adaptimmune Limited rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Adaptimmune Limited ranks #11,149 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Adaptimmune Limited hold?
Adaptimmune Limited holds 27 US utility patents granted between 2015 and 2024, spanning 9 technology areas.
What is Adaptimmune Limited's Innovation Score?
Adaptimmune Limited has an Innovation Score of 38.4 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Adaptimmune Limited focus on?
Adaptimmune Limited's top technology area is C07K (PEPTIDES) with 23 patents. Grants appear in 9 CPC subclasses total.
Is Adaptimmune Limited's patent grant rate increasing or decreasing?
Adaptimmune Limited's recent grant velocity is +70% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.
What does claim depth mean for Adaptimmune Limited's patents?
Adaptimmune Limited's patents average 13.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Adaptimmune Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Adaptimmune's 27 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Adaptimmune ranks #11,149 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.